Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.

Abstract

The Centre for the AIDS Programme of Research in South Africa 004 (CAPRISA 004) study demonstrated that vaginally applied tenofovir gel is a promising intervention for protecting women from sexually acquiring human immunodeficiency virus (HIV). However, the potential for emergence of tenofovir resistance remains a concern in women who seroconvert while using the gel despite the lack of plasma virus resistance as assessed by population sequencing during the trial. We applied highly sensitive polymerase chain reaction-based assays to screen for tenofovir resistance in plasma and vaginal swab specimens. The absence of mutation detection suggested little immediate risk of tenofovir-resistant HIV-1 emergence and forward transmission in settings in which gel users are closely monitored for HIV seroconversion.

• Authors: Xierong Wei, Gillian Hunt, Salim S Abdool Karim, Vivek Naranbhai, Sengeziwe Sibeko, Quarraisha Abdool Karim, Jin-Fen Li, Angela D M Kashuba, Lise Werner, Jo-Ann S Passmore, Lynn Morris, Walid Heneine, Jeffrey A Johnson
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 209 Issue 12 Pg. 1916-20 (Jun 15 2014) ISSN: 1537-6613 [Electronic] United States
• PMID: 24436453 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
• Copyright: Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Chemical References

• Anti-HIV Agents
• Gels
• Organophosphonates
• Vaginal Creams, Foams, and Jellies
• Tenofovir
• Adenine

Topics

• Adenine (analogs & derivatives, therapeutic use)
• Adolescent
• Adult
• Anti-HIV Agents (therapeutic use)
• Drug Resistance, Viral
• Female
• Gels (chemistry)
• HIV Infections (prevention & control, transmission)
• HIV-1 (drug effects, genetics, isolation & purification)
• Humans
• Organophosphonates (therapeutic use)
• Polymerase Chain Reaction
• South Africa
• Tenofovir
• Vagina (drug effects, virology)
• Vaginal Creams, Foams, and Jellies (pharmacology)
• Viral Load
• Young Adult